Contact The Gross Law Firm by August 25, 2025 Deadline to Join Class Action Against Sarepta Therapeutics, Inc. ( SRPT ) - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. SRPT. Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff ...
Sarepta Therapeutics ( SRPT ) August 25, 2025 Lead Plaintiff Deadline Approaching, SRPT Investors with Substantial Losses Encouraged to Contact Hagens Berman - Sarepta Therapeutics ( NASDAQ:SRPT )
SAN FRANCISCO, Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- The pending securities class action was triggered after news of safety problems with Sarepta's SRPT ELEVIDYS, a medication intended for the treatment of Duchenne muscular dystrophy.
SRPT INVESTOR NOTICE: Robbins Geller Ruman & Dowd LLP Announces that Sarepta Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit - Sarepta Therapeutics ( NASDAQ:SRPT )
SAN DIEGO, Aug. 18, 2025 ( GLOBE NEWSWIRE ) -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sarepta Therapeutics, Inc.
SRPT LOSS ALERT: Sarepta Therapeutics, Inc. Investors with Losses are Reminded of the August 25 Class Action Deadline - Contact BFA Law ( NASDAQ:SRPT ) - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 17, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. SRPT and certain of the Company's senior executives for potential violations of the federal securities laws.
SRPT IMPORTANT DEADLINE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important August 25 Deadline in Securities Class Action - SRPT - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 16, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. SRPT between June 22, 2023 and June 24, 2025, both dates inclusive ( the "Class Period" ) , of the important August 25, 2025 ...
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics - Sarepta Therapeutics ( NASDAQ:SRPT )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options
SAREPTA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm Before the August 25th Deadline - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 16, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ( "Sarepta" or the "Company" ) SRPT in the United States District Court for the ...
SRPT FRAUD REMINDER: Sarepta Therapeutics, Inc. Stock Drop Triggers Securities Fraud Class Action - Contact BFA Law before Imminent August 25 Deadline ( NASDAQ:SRPT ) - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 15, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. SRPT and certain of the Company's senior executives for potential violations of the federal securities laws.
Sarepta Sells Arrowhead Stake to Fund Milestone Payment
Sarepta sells $174M in Arrowhead shares to fund a $100M milestone payment as part of its RNAi drug collaboration.
How Do Investors Really Feel About Sarepta Therapeutics? - Sarepta Therapeutics ( NASDAQ:SRPT )
Sarepta Therapeutics's SRPT short percent of float has risen 41.95% since its last report. The company recently reported that it has 20.95 million shares sold short, which is 25.14% of all regular shares that are available for trading.
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics - Sarepta Therapeutics ( NASDAQ:SRPT )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses In Sarepta To Contact Him Directly To Discuss Their Options
SAREPTA ( SRPT ) LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ( "Sarepta" or the "Company" ) SRPT in the United States District Court for the ...
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction - Cabaletta Bio ( NASDAQ:CABA ) , Moderna ( NASDAQ:MRNA )
Vinay Prasad returns as FDA's CBER head days after resigning amid Sarepta drug controversy. Analysts see a possible softer stance on rare disease therapies under Prasad. Get ahead of next week's CPI & PPI with Chris Capre's live trading strategy session this Sunday. Register Now →
C3.ai, Destiny Tech100 And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Ambiq Micro ( NYSE:AMBQ ) , C3.ai ( NYSE:AI )
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Monday. Shares of C3.ai, Inc. AI fell sharply in pre-market trading after the company reported preliminary first-quarter revenue of $70.2 million to $70.4 million with GAAP operating loss of up to $124.9 million.
SRPT COURT NOTICE: Sarepta Therapeutics Investors may have been Affected by Fraud -- Contact BFA Law before August 25 if You Suffered Losses ( NASDAQ:SRPT ) - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 11, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. SRPT and certain of the Company's senior executives for potential violations of the federal securities laws.
Why International Money Express Shares Are Trading Higher By Around 54%; Here Are 20 Stocks Moving Premarket - ALT5 Sigma ( NASDAQ:ALTS ) , C3.ai ( NYSE:AI )
Shares of International Money Express, Inc. IMXI rose sharply in pre-market trading after Western Union announced plans to acquire Intermex for $500 million. Western Union revealed its plans to acquire Intermex, a U.S.-based company specializing in payment transfers to Latin America and the ...
SRPT DEADLINE: ROSEN, A TOP RANKED LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - SRPT - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. SRPT between June 22, 2023 and June 24, 2025, both dates inclusive ( the "Class Period" ) , of the important August 25, 2025 ...
Arrowhead ( ARWR ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Thursday, August 7, 2025 at 8:30 p.m. ETPresident and Chief Executive Officer - Dr. Christopher AnzaloneContinue reading ...
Arrowhead ( ARWR ) Q3 Revenue Drops 41%
Arrowhead Pharmaceuticals ( NASDAQ:ARWR ) , a biotechnology firm focused on developing RNA interference ( RNAi ) therapeutics, released its fiscal third-quarter earnings on August 7, 2025. The most notable news from the release was a substantial miss on both GAAP revenue and earnings for Q3 ...
Sarepta Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 25, 2025 Deadline to file Lead Plaintiff Motion.
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- The Portnoy Law Firm advises Sarepta Therapeutics, Inc. ( "Sarepta Therapeutics" or the "Company" ) ( NASDAQ.
Sarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys Deliveries
SRPT rallies after Q2 earnings and revenue beat expectations as Elevidys deliveries resume following FDA clearance.
SRPT SHAREHOLDERS: Sarepta Therapeutics Stock Drop Triggers Securities Fraud Class Action - Contact BFA Law by August 25 if You Lost Money ( NASDAQ:SRPT ) - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. SRPT and certain of the Company's senior executives for potential violations of the federal securities laws.
Sarepta Therapeutics ( SRPT ) Declines Again On EMA Recommendation to Refuse ELEVIDYS Marketing Authorization, Securities Class Action Pending - Hagens Berman - Sarepta Therapeutics ( NASDAQ:SRPT )
SAN FRANCISCO, Aug. 06, 2025 ( GLOBE NEWSWIRE ) -- On July 24, 2025, the European Medicines Agency ( "EMA" ) recommended the refusal of the marketing authorization for ELEVIDYS, Sarepta's medication intended for the treatment of Duchenne muscular dystrophy.
Sarepta Therapeutics ( SRPT ) Tops Q2 Earnings and Revenue Estimates
Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of +81.98% and +15.40%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
SAREPTA LAWSUIT ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Sarepta Therapeutics, Inc. and Encourages Investors to Contact the Firm - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ( "Sarepta" or the "Company" ) SRPT in the United States District Court for the ...
SRPT CLASS ACTION: Sarepta Therapeutics Investors that Lost Money may have been Affected by Fraud -- Contact BFA Law by August 25 Legal Deadline ( NASDAQ:SRPT ) - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 05, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. SRPT and certain of the Company's senior executives for potential violations of the federal securities laws.
Sarepta to Report Q2 Earnings: What's in Store for the Stock?
SRPT's Q2 report, set to arrive Aug. 6, is likely to have Elevidys updates, restructuring plans and sales outlook in sharp investor focus.
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer - Vor Biopharma ( NASDAQ:VOR )
CAMBRIDGE, Mass., Aug. 04, 2025 ( GLOBE NEWSWIRE ) -- Vor Bio VOR, a clinical-stage biotechnology company transforming the treatment of autoimmune diseases, today announced the appointment of Dallan Murray as Chief Commercial Officer, effective immediately.
Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer
Experienced commercial leader to shape launch strategy and global market readiness for telitacicept and future pipeline opportunities Experienced commercial leader to shape launch strategy and global market readiness for telitacicept and future pipeline opportunities ...
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 03, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. SRPT between June 22, 2023 and June 24, 2025, both dates inclusive ( the "Class Period" ) , of the important August 25, 2025 ...
SRPT LEGAL ALERT: Lose Money on Your Sarepta Therapeutics, Inc. Investment? Contact BFA Law by August 25 Class Action Deadline ( NASDAQ:SRPT ) - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 03, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. SRPT and certain of the Company's senior executives for potential violations of the federal securities laws.
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sarepta and Petco and Encourages Investors to Contact the Firm - Sarepta Therapeutics ( NASDAQ:SRPT ) , Petco Health and Wellness ( NASDAQ:WOOF )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Sarepta ( SRPT ) or PetCo ( WOOF ) To Contact Him Directly To Discuss Their Options
Sarepta Therapeutics ( SRPT ) Announces Restructuring and ELEVIDYS Black Box Warning, EMA Recommends Refusal of Marketing Authorization, Securities Class Action Pending - Hagens Berman - Sarepta Therapeutics ( NASDAQ:SRPT )
SAN FRANCISCO, Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- On July 16, 2025, Sarepta Therapeutics ( NASDAQ:SRPT ) announced a major restructuring that involves, in part, a 36% workforce reduction ( 500 employees ) and other steps to annually save about $400 million.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Sarepta Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines - SRPT - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- Pomerantz LLP announces that a class action lawsuit has been filed against Sarepta Therapeutics, Inc. ( "Sarepta" or the "Company" ) SRPT. Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ( or ...
SRPT INVESTOR REMINDER: Sarepta Therapeutics, Inc. Stock Drop Leads to Class Action - Investors with Losses Urged to Contact BFA Law by August 25 ( NASDAQ:SRPT ) - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, Aug. 01, 2025 ( GLOBE NEWSWIRE ) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Sarepta Therapeutics, Inc. SRPT and certain of the Company's senior executives for potential violations of the federal securities laws.
Will Insmed ( INSM ) Report Negative Earnings Next Week? What You Should Know
Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics - Sarepta Therapeutics ( NASDAQ:SRPT )
Faruqi & Faruqi, LLP Securities Litigation Partner James ( Josh ) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their Options
ROSEN, A LEADING LAW FIRM, Encourages Sarepta Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SRPT - Sarepta Therapeutics ( NASDAQ:SRPT )
NEW YORK, July 30, 2025 ( GLOBE NEWSWIRE ) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sarepta Therapeutics, Inc. SRPT between June 22, 2023 and June 24, 2025, both dates inclusive ( the "Class Period" ) , of the important August 25, 2025 ...
Sarepta Therapeutics ( SRPT ) Tanks 36% After 3rd Patient Death, SRPT Securities Class Action Pending - Hagens Berman - Sarepta Therapeutics ( NASDAQ:SRPT )
SAN FRANCISCO, July 30, 2025 ( GLOBE NEWSWIRE ) -- On July 18, 2025, investors saw the price of their shares in Sarepta Therapeutics, Inc. ( NASDAQ:SRPT ) collapse again - this time, shares closed down $7.89 ( -36% ) - after the company reported the death of a third patient who was being treated ...
This IonQ Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - ATAI Life Sciences ( NASDAQ:ATAI ) , IonQ ( NYSE:IONQ )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Ladenburg Thalmann initiates coverage on Comstock Inc.
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday? - Sarepta Therapeutics ( NASDAQ:SRPT ) , Capricor Therapeutics ( NASDAQ:CAPR )
After three months amid political and public pressure, Vinay Prasad resigns from the FDA's biologics center. FDA reversed Sarepta's Elevidys shipment halt just a day before Prasad's abrupt exit. The market's back, and these 3 income stocks are thriving. See them here→
Sarepta Therapeutics ( SRPT ) to Report Q2 Results: Wall Street Expects Earnings Growth
Sarepta Therapeutics (SRPT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why LendingClub Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket - Antelope Ent Hldgs ( NASDAQ:AEHL ) , AtriCure ( NASDAQ:ATRC )
Shares of LendingClub Corporation LC rose sharply in pre-market trading after the company reported better-than-expected second-quarter sales results. LendingClub reported a strong second-quarter performance, with a 156% increase in net income.
FDA Lifts Safety Hold On Sarepta's Muscular Dystrophy Gene Therapy-Wall Street Cheers - Sarepta Therapeutics ( NASDAQ:SRPT )
JP Morgan and Oppenheimer upgrade Sarepta, with forecasts of Elevidys sales reaching $500 million-$600 million from 2026 to 2028. Sarepta price targets are raised; Bernstein initiates at $13 while BMO lifts the forecast to $50. Missed the rally? Learn exactly where the next leaders are emerging ...
Crude Oil Gains Over 1%; UnitedHealth Earnings Miss Views - Durect ( NASDAQ:DRRX ) , AIM ImmunoTech ( AMEX:AIM )
U.S. stocks traded lower midway through trading, with the Nasdaq Composite falling around 0.2% on Tuesday. The Dow traded down 0.40% to 44,658.06 while the NASDAQ fell 0.22% to 21,131.59. The S&P 500 also fell, dropping, 0.20% to 6,376.82. Real estate shares jumped by 1.5% on Tuesday.
Sanmina, Sarepta Therapeutics, Polaris, Celestica And Other Big Stocks Moving Higher On Tuesday - Rich Sparkle Holdings ( NASDAQ:ANPA ) , Amkor Tech ( NASDAQ:AMKR )
U.S. stocks were mixed, with the Dow Jones index falling around 100 points on Tuesday. Shares of Sanmina Corporation SANM rose sharply during Tuesday's session after the company reported better-than-expected quarterly financial results.
This Sarepta Therapeutics Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Tuesday - Afya ( NASDAQ:AFYA ) , Allegion ( NYSE:ALLE )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. JP Morgan analyst Anupam Rama upgraded Sarepta Therapeutics, Inc.
Sarepta Therapeutics Surges Over 40% In Tuesday Pre-Market: What's Going On? - Arrowhead Pharma ( NASDAQ:ARWR ) , Sarepta Therapeutics ( NASDAQ:SRPT )
Stock of Sarepta Therapeutics Inc. SRPT surged 41.05% in Tuesday pre-market following the U.S. Food and Drug Administration's ( FDA ) recommendation to lift the voluntary hold on Elevidys, Sarepta's gene therapy for Duchenne Muscular Dystrophy.
BMNR, SRPT, CEA, SMCI, AMD: 5 Trending Stocks Today - Advanced Micro Devices ( NASDAQ:AMD )
U.S. markets closed mixed on Monday, with the Dow Jones Industrial Average slipping 0.1% to 44,837.56 and the S&P 500 holding steady at 6,389.77. The Nasdaq edged up 0.3% to finish at 21,178.58. These are the top stocks that gained the attention of retail traders and investors throughout the day.
HIMS and SRPT ALERTS: Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Hims & Hers and Sarepta and Encourages Investors to Contact the Firm - Sarepta Therapeutics ( NASDAQ:SRPT ) , Hims & Hers Health ( NYSE:HIMS )
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Hims & Hers ( HIMS ) or Sarepta ( SRPT ) To Contact Him Directly To Discuss Their Options
